Literature DB >> 27019389

Longitudinal, in vivo assessment of invasive pulmonary aspergillosis in mice by computed tomography and magnetic resonance imaging.

Jennifer Poelmans1, Amy Hillen1, Liesbeth Vanherp1, Kristof Govaerts1, Johan Maertens2, Tom Dresselaers1,3, Uwe Himmelreich1, Katrien Lagrou4, Greetje Vande Velde1.   

Abstract

Invasive aspergillosis is an emerging threat to public health due to the increasing use of immune suppressive drugs and the emergence of resistance against antifungal drugs. To deal with this threat, research on experimental disease models provides insight into the pathogenesis of infections caused by susceptible and resistant Aspergillus strains and by assessing their response to antifungal drugs. However, standard techniques used to evaluate infection in a preclinical setting are severely limited by their invasive character, thereby precluding evaluation of disease extent and therapy effects in the same animal. To enable non-invasive, longitudinal monitoring of invasive pulmonary aspergillosis in mice, we optimized computed tomography (CT) and magnetic resonance imaging (MRI) techniques for daily follow-up of neutropenic BALB/c mice intranasally infected with A. fumigatus spores. Based on the images, lung parameters (signal intensity, lung tissue volume and total lung volume) were quantified to obtain objective information on disease onset, progression and extent for each animal individually. Fungal lung lesions present in infected animals were successfully visualized and quantified by both CT and MRI. By using an advanced MR pulse sequence with ultrashort echo times, pathological changes within the infected lung became visually and quantitatively detectable at earlier disease stages, thereby providing valuable information on disease onset and progression with high sensitivity. In conclusion, these non-invasive imaging techniques prove to be valuable tools for the longitudinal evaluation of dynamic disease-related changes and differences in disease severity in individual animals that might be readily applied for rapid and cost-efficient drug screening in preclinical models in vivo.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27019389     DOI: 10.1038/labinvest.2016.45

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  40 in total

Review 1.  Techniques: magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs.

Authors:  Nicolau Beckmann; Bruno Tigani; Lazzaro Mazzoni; John R Fozard
Journal:  Trends Pharmacol Sci       Date:  2003-10       Impact factor: 14.819

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Andreas H Groll; Tin Sein; Robert L Schaufele; Andrea Francesconi; John Bacher; Nilo A Avila; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 4.  Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis.

Authors:  Taylor R T Dagenais; Nancy P Keller
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.

Authors:  Célimène Galiger; Matthias Brock; Grégory Jouvion; Amélie Savers; Marianna Parlato; Oumaïma Ibrahim-Granet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

6.  Bioluminescent Aspergillus fumigatus, a new tool for drug efficiency testing and in vivo monitoring of invasive aspergillosis.

Authors:  Matthias Brock; Grégory Jouvion; Sabrina Droin-Bergère; Olivier Dussurget; Marie-Anne Nicola; Oumaïma Ibrahim-Granet
Journal:  Appl Environ Microbiol       Date:  2008-09-26       Impact factor: 4.792

7.  Application of bioluminescence imaging for in vivo monitoring of fungal infections.

Authors:  Matthias Brock
Journal:  Int J Microbiol       Date:  2011-10-27

8.  Preclinical evaluation of two 68Ga-siderophores as potential radiopharmaceuticals for Aspergillus fumigatus infection imaging.

Authors:  Milos Petrik; Gerben M Franssen; Hubertus Haas; Peter Laverman; Caroline Hörtnagl; Markus Schrettl; Anna Helbok; Cornelia Lass-Flörl; Clemens Decristoforo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-24       Impact factor: 9.236

9.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

10.  Growth pattern analysis of murine lung neoplasms by advanced semi-automated quantification of micro-CT images.

Authors:  Minxing Li; Artit Jirapatnakul; Alberto Biancardi; Mark L Riccio; Robert S Weiss; Anthony P Reeves
Journal:  PLoS One       Date:  2013-12-23       Impact factor: 3.240

View more
  15 in total

Review 1.  Animal Models of Aspergillosis.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Comp Med       Date:  2018-04-02       Impact factor: 0.982

2.  A Multimodal Imaging Approach Enables In Vivo Assessment of Antifungal Treatment in a Mouse Model of Invasive Pulmonary Aspergillosis.

Authors:  Greetje Vande Velde; Katrien Lagrou; Jennifer Poelmans; Uwe Himmelreich; Liesbeth Vanherp; Luca Zhai; Amy Hillen; Bryan Holvoet; Sarah Belderbos; Matthias Brock; Johan Maertens
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  Bronchoscopic fibered confocal fluorescence microscopy for longitudinal in vivo assessment of pulmonary fungal infections in free-breathing mice.

Authors:  Liesbeth Vanherp; Jennifer Poelmans; Amy Hillen; Kristof Govaerts; Sarah Belderbos; Tinne Buelens; Katrien Lagrou; Uwe Himmelreich; Greetje Vande Velde
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

Review 4.  Molecular Imaging of Invasive Pulmonary Aspergillosis Using ImmunoPET/MRI: The Future Looks Bright.

Authors:  Christopher R Thornton
Journal:  Front Microbiol       Date:  2018-04-09       Impact factor: 5.640

Review 5.  Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.

Authors:  Patrick Van Dijck; Jelmer Sjollema; Bruno P Cammue; Katrien Lagrou; Judith Berman; Christophe d'Enfert; David R Andes; Maiken C Arendrup; Axel A Brakhage; Richard Calderone; Emilia Cantón; Tom Coenye; Paul Cos; Leah E Cowen; Mira Edgerton; Ana Espinel-Ingroff; Scott G Filler; Mahmoud Ghannoum; Neil A R Gow; Hubertus Haas; Mary Ann Jabra-Rizk; Elizabeth M Johnson; Shawn R Lockhart; Jose L Lopez-Ribot; Johan Maertens; Carol A Munro; Jeniel E Nett; Clarissa J Nobile; Michael A Pfaller; Gordon Ramage; Dominique Sanglard; Maurizio Sanguinetti; Isabel Spriet; Paul E Verweij; Adilia Warris; Joost Wauters; Michael R Yeaman; Sebastian A J Zaat; Karin Thevissen
Journal:  Microb Cell       Date:  2018-06-14

Review 6.  Let's shine a light on fungal infections: A noninvasive imaging toolbox.

Authors:  Katrien Van Dyck; Ona Rogiers; Greetje Vande Velde; Patrick Van Dijck
Journal:  PLoS Pathog       Date:  2020-03-05       Impact factor: 6.823

Review 7.  Molecular Imaging of Pulmonary Inflammation and Infection.

Authors:  Chiara Giraudo; Laura Evangelista; Anna Sara Fraia; Amalia Lupi; Emilio Quaia; Diego Cecchin; Massimiliano Casali
Journal:  Int J Mol Sci       Date:  2020-01-30       Impact factor: 5.923

8.  Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Authors:  Suzanne J F Kaptein; Sofie Jacobs; Lana Langendries; Laura Seldeslachts; Sebastiaan Ter Horst; Laurens Liesenborghs; Bart Hens; Valentijn Vergote; Elisabeth Heylen; Karine Barthelemy; Elke Maas; Carolien De Keyzer; Lindsey Bervoets; Jasper Rymenants; Tina Van Buyten; Xin Zhang; Rana Abdelnabi; Juanita Pang; Rachel Williams; Hendrik Jan Thibaut; Kai Dallmeier; Robbert Boudewijns; Jens Wouters; Patrick Augustijns; Nick Verougstraete; Christopher Cawthorne; Judith Breuer; Caroline Solas; Birgit Weynand; Pieter Annaert; Isabel Spriet; Greetje Vande Velde; Johan Neyts; Joana Rocha-Pereira; Leen Delang
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-09       Impact factor: 11.205

9.  Longitudinal In Vivo Assessment of Host-Microbe Interactions in a Murine Model of Pulmonary Aspergillosis.

Authors:  Shweta Saini; Jennifer Poelmans; Hannelie Korf; James L Dooley; Sayuan Liang; Bella B Manshian; Rein Verbeke; Stefaan J Soenen; Greetje Vande Velde; Ine Lentacker; Katrien Lagrou; Adrian Liston; Conny Gysemans; Stefaan C De Smedt; Uwe Himmelreich
Journal:  iScience       Date:  2019-09-18

10.  Development and multimodal characterization of an elastase-induced emphysema mouse disease model for the COPD frequent bacterial exacerbator phenotype.

Authors:  Irene Rodríguez-Arce; Xabier Morales; Mikel Ariz; Begoña Euba; Nahikari López-López; Maider Esparza; Derek W Hood; José Leiva; Carlos Ortíz-de-Solórzano; Junkal Garmendia
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.